MUVON enables healthy aging! We reverse age- or damage-related disability through functional skeletal muscle regeneration. MUVON's proprietary, tissue engineering regenerative platform technology induces successful muscle restoration, using a low-risk, minimally-invasive treatment modality, bringing personalized medicine to patients with high unmet medical need. In our first pipeline indication, we successfully completed PhI+PhII clinical trials, resulting in functional restoration of the sphincter muscle of patients, suffering from a highly-debilitating disease,stress urinary incontinence, affecting 40% women over 40 and 20% men over 60. Our platform therapy holds potential for a transformative therapeutic option. No raising SerA.
16.03.2026
SEF.WomenAward 2026: Gewinnerinnen gekürt (startupticker.ch)
18.12.2025
Executive reshuffle in ICT and Biotech startups (startupticker.ch)
03.12.2025
Four biotech startups reach key milestones (startupticker.ch)
25.11.2025
SEF.WomenAward 2026: Diese drei Gründerinnen stehen im Finale (startupticker.ch)
21.07.2025
Drei Startups verstärken ihre Verwaltungsräte (startupticker.ch)
03.12.2025
16.04.2025
10.01.2025
01.10.2022
First patient first visit Phase2
05.12.2021
No Jobs
Insights
OUR MISSION
VISION
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Website:
www.muvon-therapeutics.com
Headquarter:
Zurich
Foundation Date:
October 2020
Technology:
Sectors: